Borenius advised Valo Therapeutics on a EUR 19 million investment round led by Italian venture capital funds

We advised Valo Therapeutics Oy on its latest investment round, securing EUR 19 million to advance the clinical development of its innovative cancer immunotherapy platform. Valo Therapeutics Oy, based in Helsinki, Finland, is at the forefront of cancer immunotherapy with its PeptiCRAd platform, which enhances anti-tumour immune responses in patients with solid tumours.

The investment round was co-led by Indaco Venture Partners and CDP Venture Capital SGR, with additional support from Fondazione ENEA Tech e Biomedical and Australian investors. This funding will enable Valo to expand and complete its Phase 1B clinical trials in Italy, Australia, and Germany, and establish a new research and development centre in Naples, Italy.

Read more here.